RxDoctor Payments Data

Carlos Ramirez Calderon, MD

Neurology · Miami, FLNPI 1972586295

Payments from drug & device makers

$435,221in general payments, 2019–2025

Across 1,458 payments — averaging $298.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$194K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$104K
  • Novartis$68K
  • Sanofi$26K
  • Genentech USA, Inc.$9K
  • Acadia Pharmaceuticals Inc$8K
  • plus $27K from 53 others

What the payments were for

  • Consulting fees$1,7153%
  • Speaking & faculty fees$32,46148%
  • Travel & lodging$1,4372%
  • Food & beverage$32,24247%
  • Education$2230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.17$194,083
Otsuka Pharmaceutical Development & Commercialization, Inc.7$104,238
Novartis171$67,647
Sanofi74$25,892
Genentech USA, Inc.59$9,169
Acadia Pharmaceuticals Inc5$7,573
EMD Serono, Inc.91$3,441
Biogen128$2,817
Mallinckrodt Hospital Products Inc.90$1,926
AbbVie(2 entities)92$1,690
Banner Life Sciences, LLC30$1,298
Neurocrine Biosciences, Inc.82$1,198
UCB, Inc.34$1,172
Eisai Inc.33$942
AstraZeneca(2 entities)17$854
Amneal Pharmaceuticals LLC47$842
Teva Pharmaceuticals USA, Inc.31$768
SK Life Science, Inc.21$715
Lilly USA, LLC26$615
Johnson & Johnson(2 entities)30$606
GE HealthCare31$598
Adamas Pharmaceuticals, Inc.40$598
TG Therapeutics, Inc.12$536
Acorda Therapeutics, Inc27$528
Lundbeck LLC21$500
Kyowa Kirin, Inc.25$491
Argenx US, Inc.20$410
Bristol Myers Squibb21$388
Sunovion Pharmaceuticals Inc.16$345
Amgen(2 entities)11$283
Mallinckrodt Enterprises LLC10$249
Corium, LLC15$228
Neurelis, Inc.10$215
Takeda Pharmaceuticals U.S.A., Inc.13$203
Vertical Pharmaceuticals, LLC10$193
Otsuka America Pharmaceutical, Inc.9$188
Avion Pharmaceuticals10$173
MDD US Operations, LLC8$170
Pfizer7$157
Supernus Pharmaceuticals, Inc.6$119
GRT US Holding, Inc.4$108
Cycle Pharmaceuticals Inc5$101
Merz Pharmaceuticals, LLC5$94
Biohaven Pharmaceutical Holding Company Ltd.5$94
Biohaven Pharmaceuticals, Inc.4$91
Tanabe Pharma America, Inc.4$90
ANI Pharmaceuticals, Inc.4$89
Vanda Pharmaceuticals Inc.3$77
C2n Diagnostics, LLC3$65
Jazz Pharmaceuticals Inc.2$61
Octapharma USA, Inc.2$58
Invivyd Inc2$55
Abbott1$47
Catalyst Pharmaceuticals, Inc.1$33
Insightec,inc1$31
Upsher-smith Laboratories LLC2$29
Bausch Health US, LLC1$22
Avanir Pharmaceuticals, Inc.1$11
Sanofi-aventis U.S. LLC1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$435,221 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$686,847
Medicare patients
201
Services billed
40,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide54$565,544
Kesimpta PenOfatumumab49$511,596
CopaxoneGlatiramer Acetate48$280,416
GilenyaFingolimod Hcl15$236,127
IngrezzaValbenazine Tosylate15$120,954
Plegridy PenPeginterferon Beta-1a13$105,735
GlatopaGlatiramer Acetate29$57,144
AdlarityDonepezil Hcl73$38,579
NourianzIstradefylline17$33,034
RytaryCarbidopa/Levodopa17$17,241
Rivastigmine69$15,989
RivastigmineRivastigmine Tartrate86$5,796
Quetiapine Fumarate193$5,609
MyrbetriqMirabegron12$5,595
Primidone307$5,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$25,892$565,54454 claims
Teva Pharmaceuticals USA, Inc.Copaxone$768$280,41648 claims
NovartisGilenya$67,647$236,12715 claims
Neurocrine Biosciences, Inc.Ingrezza$1,198$120,95415 claims
Corium, LLCAdlarity$228$38,57973 claims
Kyowa Kirin, Inc.Nourianz$491$33,03417 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$842$20,26045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →